ASXL1 and acute myeloid leukemia: In 347 adult patients diagnosed with de novo acute myeloid leukemia (AML), Lin et al. observed that HOPX expression was associated with distinct clinical and molecular features such as higher platelet counts, lower white blood cell counts, lower lactate dehydrogenase levels, and mutations in the RUNX1 (RUNX family transcription factor 1), IDH2 (isocitrate dehydrogenase 2), ASXL1 (ASXL transcriptional regulator 1), and DNMT3A (DNA methyltransferase 3 alpha) genes.